Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
IDRx aims to create highly selective and aligned drug combinations to stop key tumor escape mechanisms that will support prolonged and durable responses to therapy.
BioSpace sat down with Katy Powell, a psychiatric mental health nurse practitioner in Portland, Oregon, to discuss the relative risks and benefits associated with psychedelic-assisted therapy.
The FDA granted Priority Review for omidubicel with a target action date of January 30, 2023. Omidubicel is a first-in-class, advanced NAM (nicotinamide)-enabled stem cell therapy.
August 1 is RNA Day. BioSpace takes a look at recent breakthroughs in RNA therapeutics, and the vast potential of the “vital biological molecule.”
The decision comes after the FDA put NUV-422, its candidate for high-grade gliomas, on a partial clinical hold, citing safety concerns.
The ongoing AAIC 2022 in San Diego has delivered positive news for the AD space. We look at updates from Vivoryon, Anavex and Argentinian scientists below.
Being laid off from a job is stressful. Fortunately, there are steps you can take to curb some of that stress, relieve financial worries and make finding your next position as smooth a process as possible.
Marengo Therapeutics and Ipsen have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic.
Vicinitas launched with a Series A round worth $65 million and was co-led by a16z and Deerfield Management, with participants including Droia Ventures, GV, and the Berkeley Catalyst Fund.
Innate Pharma announced that a planned futility interim analysis of the INTERLINK-1 Phase III trial sponsored by AstraZeneca failed to hit a pre-defined threshold for efficacy.
The BLA is for the use of the drug N-803 with BCG to treat patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma with or without Ta or T1 disease.
NervGen showed that its proprietary drug NVG-291-R, could repair the nervous system after a stroke in rodents —even when it was given seven days after the episode.
